Zacks Investment Research Downgrades Derma Sciences Inc. (DSCI) to Hold
Derma Sciences Inc. (NASDAQ:DSCI) was downgraded by Zacks Investment Research from a “strong-buy” rating to a “hold” rating in a note issued to investors on Tuesday.
According to Zacks, “Derma Sciences, Inc. is engaged in the development, marketing and sales of proprietary and non-proprietary topical, nutrient-based wound care products for the management of certain chronic, non-healing skin ulcerations such as pressure and venous ulcers, surgical incisions and burns. (PRESS RELEASE) “
Separately, TheStreet raised shares of Derma Sciences from a “sell” rating to a “hold” rating in a report on Tuesday, August 9th. Four investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of $7.35.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/11/zacks-investment-research-downgrades-derma-sciences-inc-dsci-to-hold-2.html
Derma Sciences (NASDAQ:DSCI) traded down 0.43% during trading on Tuesday, reaching $4.58. 10,051 shares of the company’s stock traded hands. Derma Sciences has a one year low of $2.85 and a one year high of $5.99. The firm’s 50 day moving average price is $4.71 and its 200-day moving average price is $4.19. The stock’s market cap is $129.64 million.
Derma Sciences (NASDAQ:DSCI) last announced its earnings results on Tuesday, August 9th. The company reported $0.08 EPS for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.16. The business had revenue of $22.20 million for the quarter, compared to analysts’ expectations of $22.40 million. Derma Sciences had a negative net margin of 21.19% and a negative return on equity of 11.74%. On average, equities analysts anticipate that Derma Sciences will post ($0.04) earnings per share for the current fiscal year.
Institutional investors have recently made changes to their positions in the stock. Franklin Resources Inc. boosted its position in shares of Derma Sciences by 2.5% in the first quarter. Franklin Resources Inc. now owns 2,684,500 shares of the company’s stock valued at $8,322,000 after buying an additional 65,192 shares in the last quarter. Granahan Investment Management Inc. MA boosted its position in shares of Derma Sciences by 5.1% in the first quarter. Granahan Investment Management Inc. MA now owns 1,028,460 shares of the company’s stock valued at $3,188,000 after buying an additional 50,142 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of Derma Sciences by 1.1% in the second quarter. Vanguard Group Inc. now owns 802,878 shares of the company’s stock valued at $3,163,000 after buying an additional 8,376 shares in the last quarter. Renaissance Technologies LLC boosted its position in shares of Derma Sciences by 23.3% in the first quarter. Renaissance Technologies LLC now owns 541,800 shares of the company’s stock valued at $1,680,000 after buying an additional 102,500 shares in the last quarter. Finally, BlackRock Institutional Trust Company N.A. boosted its position in shares of Derma Sciences by 2.4% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 153,052 shares of the company’s stock valued at $603,000 after buying an additional 3,613 shares in the last quarter. 62.44% of the stock is currently owned by institutional investors.
About Derma Sciences
Derma Sciences, Inc (Derma Sciences) is a medical device company. The Company operates through two segments: advanced wound care and traditional wound care products. Advanced wound care products principally consist of both novel and otherwise differentiated dressings, devices and skin substitutes designed to promote wound healing and/or prevent infection.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Derma Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Derma Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.